Posted: 2 June 2025
BioMelbourne Network is pleased to share that one of our valued members Cartherics Pty Ltd, will present at the upcoming 2025 BIO International Convention June 16-19 2025, in Boston Massachusetts. Catherics Chief Operating Officer, Dr. Ian Nisbet, will present at the renowned event.
Dr. Nisbet’s presentation, titled “Cartherics – Revolutionizing Cellular Therapies for Cancer and Beyond”, is scheduled for Monday, June 16th at 1:30 PM (US EDT) in Room 153C. He will discuss Cartherics’ innovative pipeline, research and development activities, business objectives, and investment goals.
The BIO International Convention is the world’s largest industry gathering, offering a unique opportunity to engage with senior biotech executives, business development leaders, and investors. This platform is ideal for Cartherics to showcase its cutting-edge cell therapy platform targeting ovarian cancer, endometriosis, and other indications.
Cartherics’ proprietary platform utilizes induced pluripotent stem cells (iPSC) to produce homogenous, natural killer (NK) cells through a scalable manufacturing process. These NK cells are engineered to carry chimeric antigen receptors (CARs) for precise targeting of solid tumors and potentially endometriosis. The company’s pipeline includes multiple assets with dual-targeting and immune evasion resistance, all protected by strong patents.
CTH-401, Cartherics’ lead cell therapy candidate, is the only NK cell product in development featuring a CAR targeting TAG-72, a well-established tumor marker expressed across various adenocarcinomas, including ovarian, gastric, colorectal, prostate, and pancreatic cancers. CTH-401 has demonstrated high efficacy in eliminating ovarian cancer cells in both tissue culture and animal models, with regulatory approval for the first clinical trial anticipated next year.
Dr. Nisbet commented, “Cartherics has established a powerful platform for generating an effectively unlimited supply of CAR-NK cells that are potential therapies for poorly treated and underserved diseases like cancer and endometriosis. BIO presents a fantastic opportunity to showcase this platform to the world.”
BioMelbourne Network members are constantly at the forefront of innovation in health technologies, be it Victoria, Australia, and beyond. We are pleased to share this exciting development from Cartherics and will continue to share further updates as they grow their significant impact on the industry.
About Cartherics
Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia, focused on rearming the body’s immune system to fight cancer, endometriosis, and potentially Alzheimer’s Disease. The company is developing cell-based immunotherapies with a portfolio of CAR-T and CAR-NK cell products. Cartherics’ allogeneic cell platform is based on iPSCs generated from donated cord blood, engineered to enhance the function of derived NK and other immune cells. The lead product, CTH-401, targets TAG-72 and includes gene deletions associated with immunosuppression. Cartherics has a strong pipeline aimed at disrupting ovarian cancer and endometriosis. Learn more.
About BIO
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, and related organizations globally. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest biotechnology industry gathering.
See the full press release here.
